Telesis Bio provides automated RNA and DNA synthesis platforms, such as BioXp and Gibson SOLA, that let researchers run antibody, cell‑gene therapy, and vaccine discovery workflows in‑house. By using its secure myBioXperience portal and rapid synthesis kits, labs can cut development cycles up to 90%, achieving results in as little as three days from sequence to product while maintaining high fidelity and control.
Funding
$74.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Researchers developing therapeutics and diagnostics often rely on external gene synthesis services, leading to long turnaround times, limited control over quality, and high costs that delay discovery projects.
Solution
Telesis Bio offers automated RNA and DNA synthesis platforms that enable laboratories to perform therapeutic and diagnostic discovery workflows in‑house. The BioXp system integrates with a secure myBioXperience® portal, allowing users to submit sequences, receive ready‑to‑load kits, and initiate synthesis with a single press of a button. The Gibson SOLA workflow provides rapid mRNA production, delivering results in as little as three days from sequence to functional material. By bringing synthesis internally, the platforms deliver up to 90% faster timelines, improve fidelity, and give researchers full control over quality, cost, and throughput.
Target Audience
Primary customers are academic, biotech, and pharmaceutical laboratories that conduct therapeutic antibody, cell‑ and gene‑therapy, and vaccine development projects and require rapid, high‑quality nucleic acid synthesis in‑house.
Features
- Fully automated BioXp platform for DNA and RNA synthesis with minimal hands‑on time
- Secure myBioXperience® web portal for sequence submission, kit management, and workflow tracking
- Gibson SOLA custom solution enabling three‑day mRNA synthesis from sequence to result
- High‑fidelity synthesis chemistry that supports antibody‑drug conjugates, cell‑ and gene‑therapy vectors, and vaccine candidates
- Scalable throughput suitable for both small‑scale proof‑of‑concept and larger production runs
- Integrated biosecurity compliance through membership in the International Gene Synthesis Consortium